clinical trial · NCT04770779
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
Transfusion-dependent Alpha-ThalassemiaTransfusion-dependent Beta-ThalassemiaPlacebo Matching MitapivatMitapivat
brief summary
The primary objective of this study was to compare the effect of mitapivat versus placebo on transfusion burden in participants with α- or β-transfusion-dependent thalassemia.
started
Nov 30, 2021
primary completion
Apr 11, 2024
completion
Jun 1, 2029
last updated
Apr 24, 2026
detailed description
The mitapivat group included 171 participants. The placebo group included 87 participants.
official title
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol